Critical Diagnostics
James Snider has over 30 years of work experience, starting from 1991 when they worked as a senior scientist at Boston Biomedica. James then moved on to Applied Biosystems in 1993, where they worked as a Senior Marketing Manager for nearly eight years. In 2001, they joined IntelligentMD as an Executive VP, where they were responsible for business and operations and developed medical device products for disease diagnosis and patient therapeutic management. Finally, in 2005, they became the President of Critical Diagnostics.
James Snider obtained their Bachelor of Science degree in Chemistry from Grand Valley State University, from 1980 to 1984. Afterward, they pursued their education further at the University of South Carolina, where they earned a Ph.D. in Biochemistry from 1984 to 1989.
This person is not in any teams
This person is not in any offices
Critical Diagnostics
Critical Diagnostics is a company on the cutting edge of this change, focused on the discovery, development, and commercialization of novel biomarkers in cardiovascular diseases.Their lead product, the Presage® ST2 Assay, has received FDA clearance and is CE Marked in Europe. This simple, non-invasive test measures for soluble ST2 in the blood,which can aid physicians in risk assessment of heart failure patients.Soluble ST2 has now been published in more than 100 peer-reviewed articles and scientific posters studying more than 36,000 patients. These clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death in a broad spectrum of cardiovascular disease. They have further shown that the prognostic information from soluble ST2 is independent and provides added information to the cardiac biomarkers commonly used today, including the natriuretic peptides, BNP and NT-proBNP.Critical Diagnostics was founded in 2004. The Company licensed intellectual property discovered in 2002 at Brigham and Women's Hospital relating to ST2, for which it now holds the exclusive worldwide rights. The company has since expanded its intellectual property portfolio and holds several issued patents in the US and abroad as well as numerous patents pending.